BIG
ARQT icon

Brooklyn Investment Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Brooklyn Investment Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-8,382
Closed -$239K – 1842
2025
Q4 		$239K Buy
+8,382
New +$215K 0.01% 1223
2025
Q3 		– Sell
-391
Closed -$5.48K – 801
2025
Q2 		$5.48K Buy
391
+377
+2,693% +$5.29K ﹤0.01% 2431
2025
Q1 		$219 Sell
14
-330
-96% -$4.65K ﹤0.01% 2615
2024
Q4 		$4.79K Buy
+344
New +$3.77K ﹤0.01% 1226

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Brooklyn Investment Group's ARQT Position: Q1 2026 in Review

Brooklyn Investment Group sold out of Arcutis Biotherapeutics (ARQT) in Q1 2026, closing a stake of 8,382 shares — an estimated $239K sold.

Brooklyn Investment Group first reported a position in ARQT in Q4 2024 and held it in 4 quarters. The position peaked at $239K in Q4 2025. 270 funds tracked by Wall St. Rank hold ARQT as of Q1 2026.

  • Brooklyn Investment Group reported no remaining Arcutis Biotherapeutics position as of Q1 2026 after selling out during the quarter.
  • Brooklyn Investment Group sold 8,382 Arcutis Biotherapeutics shares in Q1 2026, an estimated $239K.
  • Brooklyn Investment Group first reported a position in Arcutis Biotherapeutics in Q4 2024 and held it in 4 quarters.
  • Brooklyn Investment Group's Arcutis Biotherapeutics position peaked at $239K in Q4 2025.
  • 270 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q1 2026.

Based on Brooklyn Investment Group's 13F filing for Q1 2026, filed 29 Apr 2026.